Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Cassava Sciences Inc (FLNA) Price & Performance

Allbirds IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Cassava Sciences Inc — how do they compare? Allbirds Inc trades at $2.6 (market cap $22.68M), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Cassava Sciences Inc is far larger — about 2.1× Allbirds Inc's market cap. Which is the better fit depends on your goals.

BIRDFLNA
Market Cap
$22.68M$47.75M
Sector
Consumer CyclicalHealth
52-Week High
$16.99$4.64
52-Week Low
$2.21$0.87
Enterprise Value
$41.54M-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD (Smartbird) trades at $2.53, up 5.42% with a bullish technical signal despite mixed earnings. The company completed a strategic pivot from footwear to AI infrastructure in June 2026, appointing former AWS executive Nadia Carlsten as CEO. While revenue declined to $152M in 2025 with a -53.4% net margin, the P/S ratio of 0.15 suggests potential undervaluation relative to AI sector peers.

The outlook hinges on successful execution of the AI infrastructure strategy, though significant execution risks remain given negative cash flows and lack of profitability. Analyst consensus shows cautious optimism with 21% buy ratings amid high institutional hold positions. Near-term catalysts include new board appointments and AI business development progress.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA